Author + information
- Received April 24, 1990
- Revision received August 29, 1990
- Accepted September 14, 1990
- Published online February 1, 1991.
- Thomas Behrenbeck, MD, PhD*,1,
- Patricia A. Pellikka, MD1,
- Kenneth C. Huber, MD1,
- John F. Bresnahan, MD, FACC1,
- Bernard J. Gersh, MBChB, D Phil, FACC1 and
- Raymond J. Gibbons, MD, FACC1
- ↵*Address for reprints: Thomas Behrenbeck, MD, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Technetium-99m-hexakis-2-methoxy-2-isobutyl-isonitrile (techne-tium-99m isonitrile) is a new radiopharmaceutical compound that reflects myocardial perfusion. Its kinetics, especially its lack of redistribution after intravenous administration, permits the assessment of changes in myocardial perfusion without delay of therapy. Tomographic images at rest were obtained immediately and 6 to 10 days later in 17 consecutive patients undergoing successful primary angioplasty during their first transmural myocardial infarction. Thirteen patients had anterior infarction.
The initial (acute) defect size before angioplasty of 48 ± 17% of the left ventricle decreased significantly (p < 0.0001) to 29 ± 19% on the late scans. There was no correlation between the time to therapy and the reduction in defect size. Twelve of the 17 patients, including 7 of the 11 patients treated after 4 h, demonstrated a definite reduction in the initial defect size. Eight patients with angiographically proved persistent coronary occlusion underwent a similar imaging sequence. The initial defect size in this group remained unchanged on the late scans (24 ± 16% versus 26 ± 18%, p = NS). Primary angioplasty is an effective approach toward salvaging myocardium; comparison with thrombolytic drug therapy must await the results of controlled clinical trials.
- Received April 24, 1990.
- Revision received August 29, 1990.
- Accepted September 14, 1990.
- American College of Cardiology Foundation